scholarly journals Viral coinfection in the oral cavity of HIV-infected children: relation among HIV viral load, CD4+T lymphocyte count and detection of EBV, CMV and HSV

2005 ◽  
Vol 19 (3) ◽  
pp. 228-234 ◽  
Author(s):  
Liliane Janete Grando ◽  
Denise Cantarelli Machado ◽  
Silvia Spitzer ◽  
Sharon Nachman ◽  
Fred Ferguson ◽  
...  
Keyword(s):  
New York ◽  
Viral Load ◽  
Oral Cavity ◽  
T Lymphocyte ◽  
Lymphocyte Count ◽  
Viral Infections ◽  
University Hospital ◽  
State University ◽  
Hiv Viral Load ◽  
Viral Coinfection

Viral coinfection in the oral cavity associated to HIV infection was evaluated in 180 children from birth to 13 years of age of both sexes. The oral examinations were performed at the Pediatric AIDS Outpatient Clinic, São Lucas Hospital and Clinic Hospital, both in Porto Alegre, Brazil and at the School of Dental Medicine, University Hospital Center, State University of New York at Stony Brook, USA. The aim of this study was to identify the presence of viral infections in the oral cavity. PCR technique was used to determine opportunistic viral infections caused by CMV, EBV, and HSV in mucosal swabs. A high frequency of viral infection was detected in the oral cavity of HIV-infected children determined by the PCR technique. HIV-infected children with viruses had a favorable CD4+T lymphocyte count and unfavorable viral load.

EFFECT OF IMMUNOMODULATORY HERBAL MEDICINAL PREPARATIONS ON CD4 + LYMPHOCYTE COUNT AND TOTAL VIRAL LOAD IN HIV-INFECTED INDIVIDUALS

INDIAN DRUGS ◽  
2012 ◽  
Vol 49 (07) ◽  
pp. 42-48
Author(s):  
S. T. Tharakan ◽  
◽  
G Kuttan ◽  
R. Kuttan ◽  
M. Kesavan ◽  
...  
Keyword(s):  
Renal Function ◽  
Body Weight ◽  
Viral Load ◽  
Hiv Infection ◽  
T Lymphocyte ◽  
Lymphocyte Count ◽  
Clinical Status ◽  
Hiv Patients ◽  
Herbal Formulation ◽  
Hematological Analysis

This study was carried out to determine the effect of herbal medication on the clinical status of HIV infected persons especially on their CD4+ T lymphocyte count and viral load. The toxicity of the medication was also studied. 25 HIV positive individuals were taken for the study. They were treated with a herbal formulation developed in our centre, for one year. Patients were evaluated for their clinical status every month and CD4+ T lymphocyte and viral load every six months. Other parameters assessed were body weight, hematological analysis and hepatic and renal function tests. Body weight was found to be increased in 20 patients out of 25 who have undergone treatment. CD4+T lymphocyte count was increased in 15 patients and viral load was decreased in 20 patients. In six patients viral load was undetectable range. Administration of these medications significantly reduced, elevated interferon-? and tumor necrosis factor in HIV patients. Medication did not produce any toxicity in HIV patients, as it did not show any significant change in hepatic function, renal function and haematology. Administration of herbal preparation was found to reduce clinical symptoms produced by HIV infection. This herbal formulation was found useful therapeutically for the management of HIV infection and did not produce any toxicity.

Outcomes by sex following treatment initiation with darunavir/cobicistat in a large Spanish cohort of the CODAR study (GeSIDA 9316)

2019 ◽  
Vol 74 (10) ◽  
pp. 3044-3048
Author(s):  
M J Pérez Elías ◽  
B Alejos ◽  
M J Vivancos ◽  
E Ribera ◽  
M J Galindo ◽  
...  
Keyword(s):  
Viral Load ◽  
Lymphocyte Count ◽  
Ethics Committees ◽  
Hiv Viral Load ◽  
Women Living With Hiv ◽  
Load Response ◽  
Cd4 Lymphocyte Count ◽  
Previous Regimen ◽  
Cd4 Lymphocyte ◽  
Viral Load Response

Abstract Background Few women have been included in darunavir/cobicistat clinical development studies, and hardly any of them were antiretroviral experienced or treated with anything other than triple-based therapies. Objectives Our aim was to increase our knowledge about women living with HIV undergoing darunavir/cobicistat-based regimens. Methods A multicentre (21 hospitals), retrospective study including a centrally selected random sample of HIV-1 patients starting a darunavir/cobicistat-based regimen from June 2014 to March 2017 was planned. Baseline characteristics, 24 and 48 week viral load response (<50 copies/mL), CD4+ lymphocyte count increase, time to change darunavir/cobicistat and adverse event occurrence were all compared by sex. The study was approved by each of the 21 ethics committees, and patients signed informed consent. Results Out of 761 participants, 193 were women. Similar characteristics were found for both sexes, except that the women had a longer duration of HIV infection (P = 0.001), and were less frequently pre-treated with darunavir/cobicistat in their previous regimen (P = 0.02). The main reason for using a darunavir/cobicistat-based regimen was simplification, without differences by sex, while monotherapy seems to be more frequently prescribed in women than in men (P = 0.067). The main outcomes, HIV viral load response, CD4+ lymphocyte count increase at 24 or 48 weeks, occurrence of adverse events, main reasons for changing and time to the modify darunavir/cobicistat regimen, did not show differences between the sexes. Conclusions No sex disparities were found in the main study outcomes. These results support the use of a darunavir/cobicistat-based regimen in long-term pre-treated women. Clinical Trial.gov No. NCT03042390.

GBV-C/HIV-1 coinfection is associated with low HIV-1 viral load and high CD4+ T lymphocyte count

2017 ◽  
Vol 162 (11) ◽  
pp. 3431-3438 ◽  
Author(s):  
Bárbara Katharine Barbosa de Miranda ◽  
Keyla Santos Guedes de Sá ◽  
Andrea Nazaré Rangel da Silva ◽  
Rosimar Neris Martins Feitosa ◽  
Izaura Maria Vieira Cayres-Vallinoto ◽  
...  
Keyword(s):  
Viral Load ◽  
T Lymphocyte ◽  
Lymphocyte Count ◽  
Hiv 1

scholarly journals Evaluation of HIV Viral Load Activity at the Bacteriology-Virology Laboratory in the University Hospital Center of Brazzaville

2019 ◽  
Vol 09 (04) ◽  
pp. 178-185
Author(s):  
Esther Nina Ontsira Ngoyi ◽  
Tanguy Mieret ◽  
Roland Bienvenu Ossibi Ibara ◽  
Axel Aloumba ◽  
Géril Obili Sekangue ◽  
...  
Keyword(s):  
Viral Load ◽  
University Hospital ◽  
Hiv Viral Load ◽  
The University ◽  
Hospital Center

scholarly journals Assessment of HIV disease progression before and after initiation of anti­retroviral therapy by CD4 & CD8 T-lymphocyte count and viral load assay

2016 ◽  
Vol 6 (1) ◽  
pp. 48
Author(s):  
Sahina Tabassum ◽  
S.M. Rashed-ul Islam ◽  
Afzalun Nessa ◽  
Munira Jahan ◽  
Saif Ullah Munshi
Keyword(s):  
Viral Load ◽  
T Lymphocyte ◽  
Lymphocyte Count ◽  
Published Data ◽  
Art Initiation ◽  
Cd8 T Lymphocyte ◽  
Virological Outcome ◽  
Before And After ◽  
Study Population ◽  
The Mean

<p><strong>Backgrounds:</strong> As there is no published data regarding the response to Anti-retroviral therapy (ART) among HIV patients from Bangladesh. The present study was designed to determine the immunological and virological responses of HIV infected Bangladeshi adults starting ART. Objectives: To monitor the changes of CD4 and CD8 T-lymphocyte count and Viral load (VL) before and after three and six months of starting ART.</p><p><strong>Methods:</strong> 20 symptomatic HIV infected patients with CD4 T-lymphocyte count of &lt;350 cells/µ] of blood were initiated ART.CD4 and CDS T-lymphocyte counts were estimated by Flowcytometer and VL was dete1mined by real-time PCR technique.</p><p><strong>Results:</strong> The mean CD4 T-lymphocyte count among the sn1dy patients were 177±127 cells/µl before initiation of ART. After ART initiation, their mean CD4 count increased significantly to 368±181 and 452±183 cellshll after three and six months respectively (P&lt;0.0001).The mean CDS T-lymphocyte counts were 901±650 cells/µ! before initiation of ART, which increased to I 085±393 and 1121±372 cells/µl after three and six months respectively after ART initiation (P&gt;0.05). Before ART initiation, the mean VL was 5.25±1.19 log10 (copies/ml) among the study population which became undetectable in 15 (75%) patients after three months of ART and in another 2 (10%) patients after 6 months of ART initiation.</p><p><strong>Conclusion:</strong> Our study concluded that, ART is effective in slowing the progression of HIV infection to AIDS with good immunological and virological outcome among the ART initiators.</p>

Fluctuations in HIV-1 Viral Load Are Correlated to CD4+ T-Lymphocyte Count During the Natural Course of Infection

2000 ◽  
Vol 23 (5) ◽  
pp. 375-379 ◽  
Author(s):  
Joanna Masel ◽  
Ramy A. Arnaout ◽  
Thomas R. O'Brien ◽  
James J. Goedert ◽  
Alun L. Lloyd
Keyword(s):  
Viral Load ◽  
T Lymphocyte ◽  
Lymphocyte Count ◽  
Natural Course ◽  
Hiv 1

scholarly journals Driving Force of Covid-19 Among People Living With HIV/AIDS in Wuhan, China

2020 ◽  
Author(s):  
Wei Guo ◽  
Fangzhao Ming ◽  
Yu Dong ◽  
Qian Zhang ◽  
Lian Liu ◽  
...  
Keyword(s):  
T Lymphocyte ◽  
Lymphocyte Count ◽  
Driving Force ◽  
Driving Forces ◽  
People Living With Hiv ◽  
Hiv Diagnosis ◽  
Hiv Viral Load ◽  
Increased Risk ◽  
Living With Hiv ◽  
Hiv Aids

Abstract Background: Even people living with HIV/AIDS (PLWHA) were considered to be at increased risk of SARS-CoV-2 infection, the driving force among this group of individuals is still not clear. Methods: We investigated 1,701 PLWHA through a telephone interview and found 11 COVID-19 patients in four districts of Wuhan, China. The demographic features and major clinical characteristics of these patients were retrieved from the information management systems for COVID-19 patients of four districts’ CDC. Statistical analysis was performed to find out the driving force of COVID-19 among PLWHA.Results: The incidence proportion of COVID-19 in PLWHA is 0.6% (95% CI: 0.2% - 1.0%), which is comparable to the overall population incidence rate in Wuhan city (0.6%). Nine out of the 11 COVID-19/AIDS patients had relatively high CD4+ T lymphocyte count (>200/μl) and undetectable HIV viral load (＜20 copies/ml), and ten of them were on antiretroviral therapy. PLWHA who were old, had low CD4+ T lymphocyte count, infected HIV through homosexual activity, and had been diagnosed for HIV for a long time, were more likely to develop COVID-19.Conclusions: PLWHA has comparable COVID-19 morbidity rates as the general population, and older age, low CD4 count, long length since HIV diagnosis, and treatment-naive were potential driving forces of COVID-19 occurrence among PLWHA. Strategies in preventing SARS-CoV-2 infection among PLWHA with worse immune responses are needed. Article Summary Line: As COVID-19 continues to spread around the world, people living with HIV/AIDS (PLWHA) are also at risk of infection with SARS-CoV-2. We investigated the factors associated with SARS-CoV-2 infection among PLWHA in Wuhan, China.

Different Kinetics of Immunologic Recovery Using Nelfinavir or Lopinavir/Ritonavir-Based Regimens in Children with Perinatal HIV-1 Infection

2005 ◽  
Vol 18 (4) ◽  
pp. 729-735 ◽  
Author(s):  
M. De Luca ◽  
G. Miccinesi ◽  
E. Chiappini ◽  
M. Zappa ◽  
L. Galli ◽  
...  
Keyword(s):  
Viral Load ◽  
T Lymphocyte ◽  
Highly Active Antiretroviral Therapy ◽  
Lymphocyte Count ◽  
Virologic Failure ◽  
Undetectable Viral Load ◽  
Baseline Viral Load ◽  
Perinatal Hiv ◽  
Significant Difference ◽  
Hiv 1

The choice to include the optimal protease inhibitor (PI) in highly active antiretroviral therapy (HAART) regimens in children with perinatal HIV-1 infection is still under debate. Virologic and immunologic outcomes of three different regimens in an observational paediatric cohort were compared. Data from 12 saquinavir-, 18 nelfinavir-, and 10 lopinavir/ritonavir-treated children were analyzed after 4 and 24 weeks of therapy. Immunologic and virologic outcomes were compared using multivariate analysis adjusting the results for age, baseline CD4+ T-lymphocyte count and baseline viral load. Saquinavir-treated children displayed significant reduction in viral load at week 24 (but not at week 4) and no increase in CD4+ T-lymphocyte count, indicating a poor advantage in using this drug. Lopinavir/ritonavir-treated children presented lower viral loads than nelfinavir-treated children at week 4 (P=0.020) and week 24 (p<0.0001). Virologic failure occurred in 6/18 (33.3%) nelfinavir-treated children but in no child receiving lopinavir/ritonavir (P=0.013). An undetectable viral load was achieved in 9/10 (90.0%) lopinavir/ritonavir- vs. 3/18 (16.6%) nelfinavir-treated children (p<0.0001). No significant difference in CD4+ T-lymphocyte count was observed between lopinavir/ritonavir- and nelfinavir-treated children at weeks 4 and 24. However, a different kinetic of the immunologic recovery was observed. Lopinavir/ritonavir-treated children displayed higher CD4+ T-lymphocyte counts than saquinavir-treated children since the first month of therapy (week 4: P=0.042; week 24: P= 0.029) while nelfinavir-treated children took 24 weeks to reach such an outcome (P=0.034). Since lopinavir/ritonavir-based regimen controls viral replication more efficiently and restores CD4+ T-lymphocyte count more quickly than saquinavir- or nelfinavir-based HAART, it may be considered when a salvage therapy or a rapid increase in CD4+ T-lymphocytes is necessary.

Sign in / Sign up

Export Citation Format

Share Document